BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30747109)

  • 21. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
    Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
    Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
    [No Abstract]   [Full Text] [Related]  

  • 22. Multidetector-row computed tomography assessment of adding budesonide/formoterol to tiotropium in patients with chronic obstructive pulmonary disease.
    Yasui H; Inui N; Furuhashi K; Nakamura Y; Uto T; Sato J; Yasuda K; Takehara Y; Suda T; Chida K
    Pulm Pharmacol Ther; 2013 Jun; 26(3):336-41. PubMed ID: 23340058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.
    Eriksson G; Calverley PM; Jenkins CR; Anzueto AR; Make BJ; Lindberg M; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1457-1468. PubMed ID: 28553098
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
    Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.
    Celli BR; Tashkin DP; Rennard SI; McElhattan J; Martin UJ
    Respir Med; 2011 Aug; 105(8):1176-88. PubMed ID: 21531124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-acting beta2-agonists for chronic obstructive pulmonary disease.
    Appleton S; Smith B; Veale A; Bara A
    Cochrane Database Syst Rev; 2000; (2):CD001104. PubMed ID: 10796594
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD.
    Cazzola M; Santus P; Di Marco F; Carlucci P; Mondoni M; Matera MG; Centanni S
    Pulm Pharmacol Ther; 2004; 17(3):121-5. PubMed ID: 15123220
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of concomitant inhaled corticosteroids: pooled data from two phase III studies of aclidinium plus formoterol in COPD.
    D'Urzo A; Singh D; Garcia Gil E
    NPJ Prim Care Respir Med; 2017 Feb; 27(1):13. PubMed ID: 28235977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of adding budesonide/formoterol to ipratropium plus theophylline in managing severe chronic obstructive pulmonary disease: an open-label, randomized study in China.
    Huang K; Guo Y; Kang J; An L; Zheng Z; Ma L; Peng L; Wang H; Su R; Itoh Y; Wang C
    Ther Adv Respir Dis; 2019; 13():1753466619853500. PubMed ID: 31240995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
    Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
    Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tiotropium plus formoterol versus tiotropium alone for stable moderate-to-severe chronic obstructive pulmonary disease: A meta-analysis.
    Zou Y; Xiao J; Lu XX; Xia ZA; Xie B; Li J; Chen Q
    Clin Respir J; 2018 Jan; 12(1):269-278. PubMed ID: 27402142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Aclidinium/Formoterol versus Tiotropium in COPD: Results of an Indirect Treatment Comparison.
    Medic G; Lindner L; van der Weijden M; Karabis A
    Adv Ther; 2016 Mar; 33(3):379-99. PubMed ID: 26883661
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic and bronchodilator effects of inhaled rac-formoterol in subjects with chronic obstructive pulmonary disease: a dose-response study.
    Whale CI; Sovani MP; Mortimer KJ; Harrison TW; Tattersfield AE
    Br J Clin Pharmacol; 2008 Jun; 65(6):841-7. PubMed ID: 18394012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD.
    Morgan AR; Parker GJ; Roberts C; Buonaccorsi GA; Maguire NC; Hubbard Cristinacce PL; Singh D; Vestbo J; Bjermer L; Jögi J; Taib Z; Sarv J; Bruijnzeel PL; Olsson LE; Bondesson E; Nihlén U; McGrath DM; Young SS; Waterton JC; Nordenmark LH
    Eur J Radiol; 2014 Nov; 83(11):2093-101. PubMed ID: 25176287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.